Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aura Biosciences (AURA) EBIT (2020 - 2026)

Aura Biosciences filings provide 7 years of EBIT readings, the most recent being -$34.9 million for Q1 2026.

  • Quarterly EBIT fell 20.08% to -$34.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$28.1 million through Mar 2026, down 12.67% year-over-year, with the annual reading at -$22.3 million for FY2025, 22.21% down from the prior year.
  • EBIT hit -$34.9 million in Q1 2026 for Aura Biosciences, down from $63.3 million in the prior quarter.
  • Across five years, EBIT topped out at $63.3 million in Q4 2025 and bottomed at -$34.9 million in Q1 2026.
  • Average EBIT over 5 years is -$13.0 million, with a median of -$20.5 million recorded in 2023.
  • The largest annual shift saw EBIT plummeted 116.15% in 2022 before it soared 302.07% in 2024.
  • Aura Biosciences' EBIT stood at -$17.6 million in 2022, then tumbled by 40.71% to -$24.8 million in 2023, then surged by 302.07% to $50.1 million in 2024, then increased by 26.35% to $63.3 million in 2025, then tumbled by 155.1% to -$34.9 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's EBIT are -$34.9 million (Q1 2026), $63.3 million (Q4 2025), and -$27.9 million (Q3 2025).